H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs Institute for Cancer Research

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
Institute for Cancer Research
PARank #FEIN 23-6296135

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPInstitute for Cancer Research
Total filings80,813141
Certified %98.23%82.98%
Denied %1.09%9.22%
Withdrawn %0.61%0.00%
Cert-withdrawn %0.07%7.80%
Rank#4
Active yearsFY2010–FY2026FY2012–FY2026
Worksite statePAPA

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — Institute for Cancer Research

DOL case-status mix.

Outcome breakdown: Certified 83.0%, Cert-withdrawn 7.8%, Denied 9.2%
Outcome breakdown
OutcomeShare
Certified83.0%
Cert-withdrawn7.8%
Denied9.2%
Certified83.0%
Cert-withdrawn7.8%
Denied9.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
Institute for Cancer Research
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20100
FY20110
FY201211
FY201323
FY201411
FY20159
FY20165
FY201717
FY201814
FY201915
FY20201
FY20210
FY20220
FY20230
FY202415
FY202512
FY20268

Top 5 occupations — Deloitte Consulting LLP

Top 5 occupations — Institute for Cancer Research

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.